Table 3 Characteristics of patients and outcomes of phase III clinical trials with PARP inhibitors in first line

From: SEOM clinical guideline in ovarian cancer (2020)

  SOLO-1 PAOLA-1 PRIMA VELIA
Intervention arm Olaparib
300 mg BID
Olaparib
300 mg BID
 + Bevacizumab
Niraparib
300 or 200 mg QD
Veliparib
150 BID C 1–6 and 400 mg BID cycle 7–36
Control arm Placebo Bevacizumab Placebo Placebo
Duration PARPi 2 years 2 years 3 years 36 cycles
(27 months)
FIGO     
 Stage III 85–80% 69–70% 62–65% 77–78%
 Stage IV 15–20% 30–31% 34–38% 22–23%
NACT NR 41–42% 63–67% 26–29%
Residual disease 21–22% 29–41% 100% in stage III with PDS 30–32%
Biomarkers 100% BRCAm 29% BRCAm
48% HRD
31% BRCAm
51% HRD
27–31%BRCAm
63% HRD
HR in overall population NA 0.59 0.62 0.68
HR in BRCAm 0.30 0.31 0.40 0.44
HR in HRD and BRCAwt NA 0.43 0.50 p = n.s.
HR in HRP NA p = n.s. 0.68 p = n.s.
  1. NACT neoadjuvant chemotherapy, HR hazard ratio, BRCAm BRCA mutated; BRCAwt BRCA wild type, HRD homologous recombination deficiency, HRP homologous recombination proficiency, PDS primary debulking surgery, NA not Applicable, n.s. not significant